Lung cancer is an awful disease which annually kills around 1.8m people worldwide. Worse still, around 40% of those patients deemed at risk from indeterminant lung nodules are diagnosed incorrectly using CT scans.
In this interview, CEO Paul Pagano explains why Lunglife AI‘s (LLAI ) ground-breaking technology could literally transform the early diagnosis of this terrible condition.
What the science does & how it works. Start
Accuracy of the LungLB test vs existing standard of care. 03:03
Advantages of using Circulating Tumour Cells. 03:51
Size of addressable market. 06:15
Progress of 425 person validation trial. 09:04
Is FDA approval required? 11:27
Difference between validation & utility studies. 12:22
Significance of New York Clinical Laboratory Evaluation Programme permit. 14:41
Timeline to 1st revenues. 16:01
International opportunities. 17:41
Funding runway. 18:57
Future newsflow. 20:40